- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Sodium Nitroprusside Safe and Effective for Advanced Heart Failure Patients, Study Finds
![Sodium Nitroprusside Safe and Effective for Advanced Heart Failure Patients, Study Finds Sodium Nitroprusside Safe and Effective for Advanced Heart Failure Patients, Study Finds](https://medicaldialogues.in/h-upload/2024/09/10/750x450_251859-heart-failure.webp)
Italy: A recent study published in Vascular Pharmacology has demonstrated that sodium nitroprusside (SNP) infusion is a promising and safe treatment option for patients with advanced heart failure (AdvHF), with or without concurrent inotropic support. This finding marks a significant development in managing this complex and challenging condition.
"Our findings emphasize the potential of nitroprusside to enhance systemic and renal perfusion in these advanced patients," the researchers wrote.
Heart failure, particularly in its advanced stages, presents numerous challenges for both patients and healthcare providers, especially when mechanical circulatory support or transplant options are not available, underscoring a gap in evidence-based medical management. Traditional treatments often fall short of addressing severe symptoms and improving outcomes. Sodium nitroprusside, a potent vasodilator, has been under investigation for its potential to enhance systemic and renal perfusion in these critically ill patients.
Against the above background, Stefano Ghio, Division of Cardiology, Fondazione IRCCS Policlinico S.Matteo, Pavia, Italy, and colleagues aimed to evaluate the effectiveness and safety of SNP for enhancing systemic and renal perfusion in patients with AdvHF, with or without concomitant inotropic support.
For this purpose, the researchers retrospectively examined the medical records of 406 patients with advanced heart failure (AdvHF) admitted between October 2014 and September 2018 who received nocturnal sodium nitroprusside (SNP) infusions for at least one week. In 55 patients who exhibited symptomatic hypotension or signs of peripheral hypoperfusion (differential systemic blood pressure < 15 mmHg), continuous dobutamine infusion was added. Additionally, for a subset of 155 patients who required multiple hospitalizations (median of 3), data from their most recent hospitalization were analyzed.
The following were the key findings of the study:
- No symptomatic hypotension leading to discontinuation of SNP (mean dose: 0.5 ± 0.1 μg/kg/min) was reported.
- Patients showed a significant increase in differential systemic blood pressure after infusion (29.2 ± 8.1 to 36.8 ± 11.6 mmHg) independent of dobutamine use.
- Administration of SNP and dobutamine resulted in greater weight loss than SNP alone (−5.33 ± 7.02 versus −3.32 ± 4.0 kg). However, it was also associated with a significant increase in creatinine levels compared to SNP alone (+0.24 ± 0.87 versus +0.02 ± 0.43).
"Sodium nitroprusside therapy is a safe and effective treatment option for patients with advanced heart failure (AdvHF). SNP can enhance systemic perfusion and, when used without inotropic support, may help prevent worsening renal function during hospitalization," the researchers wrote.
"These findings underscore the need for further investigation into SNP therapy through randomized clinical trials to fully explore its benefits in AdvHF. SNP can be administered safely either alone or in combination with dobutamine for patients showing signs of systemic hypoperfusion," they concluded.
Reference:
Ghio, S., Traversi, E., Maestri, R., Camporotondo, R., Caporotondi, A., Caprino, A., Fasolino, A., Guazzotti, G., Scelsi, L., Turco, A., & La Rovere, M. T. (2024). Sodium nitroprusside infusion in patients with advanced heart failure. Vascular Pharmacology, 156, 107395. https://doi.org/10.1016/j.vph.2024.107395
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751